Experiencia del Hospital Universitario de Canarias con pacientes tratados con plasmaféresis / Patients treated with plasmapheresis: a case review from University Hospital of the Canary Islands

Introducción: La plasmaféresis (PF) es una técnica de aféresis terapéutica utilizada en el tratamiento de diversas enfermedades renales y sistémicas con distintos grados de eficacia clínica demostrada. Objetivo: Analizar los resultados globales de la indicación de PF en el Hospital Universitario de Canarias, enfocados a resultados de su efectividad y seguridad en diversos grupos de enfermedades. Material y métodos: Se trata de un análisis descriptivo retrospectivo de una serie de casos que analiza los resultados de la indicación de PF desde el uno de enero de 2006 hasta el 31 de diciembre de 2009 en nuestro centro. Se revisaron las historias clínicas y se recogieron datos demográficas (sexo y edad), parámetros bioquímicos, enfermedad de base, volumen y tipo de reposición utilizado en la sesión de PF (albúmina humana al 5% y/o plasma fresco congelado), complicaciones asociadas con la técnica, días transcurridos desde la sospecha clínica diagnóstica hasta el inicio de la técnica de aféresis, número de sesiones de PF recibidas, mortalidad del paciente, grado de afectación renal y evolución de la función renal. Resultados: Estudiamos a 51 pacientes, de 50 ± 18 años, el 60% eran hombres, 331 sesiones de PF. Las enfermedades tratadas se agruparon como: 11 vasculitis, 15 inmunoactivaciones del trasplante renal, cinco síndromes hemolítico urémicos, siete casos de púrpura trombótica trombocitopénica o idiopática, dos inmunizaciones Rh fetal, dos enfermedades hematológicas y cuatro casos de enfermedades neurológicas, entre otras. La mortalidad global fue del 19,6 % (n = 10); en seis de los casos, secundaria a shock séptico y en el resto como resultado de la evolución de la enfermedad de base y uno por shock hemorrágico en el área de la biopsia renal. No hubo fallecimientos en el grupo de inmunoactivación del trasplante. En el grupo de vasculitis se produjeron tres fallecimientos (dos de ellos secundarios a un shock séptico). Nueve de los 10 pacientes que fallecieron lo hicieron dentro de los tres primeros meses tras el diagnóstico. De las 26 biopsias renales realizadas, las indicaciones más frecuentes fueron: vasculitis (23%), rechazos humorales (42%), rechazo humoral más toxicidad por anticalcineurínicos (12%) y síndrome hemolítico-urémico (8%), entre otros. Veinticuatro pacientes precisaron hemodiálisis al inicio del cuadro clínico, nueve de los 11 pacientes con vasculitis, cuatro de los cinco pacientes con síndrome hemolítico-urémico y cinco de los 15 pacientes con inmunoactivación del trasplante. Al final de la evolución, 14 de ellos permanecieron en programa de hemodiálisis. Concretamente, cinco de 11 pacientes con vasculitis, dos de 15 pacientes sometidos a trasplante y tres de cinco pacientes con síndrome hemolítico-urémico. De forma significativa, los pacientes que evolucionaron hacia enfermedad renal terminal en el grupo de las vasculitis eran de mayor edad y tenían una mayor creatinina en el comienzo de la enfermedad. En los pacientes sometidos a trasplante en quienes se monitorizaron anticuerpos anti-HLA de clases I o II medidos por luminex pre y post-PF se objetivó una media de descenso del título de anticuerpos en todos excepto en un caso; el descenso medio fue del 51 al 31%. En general, la técnica de PF transcurrió prácticamente libre de complicaciones. Se constataron cinco reacciones al plasma fresco (3%) de carácter leve-moderado (hormigueo peribucal y reacciones urticariformes) que requirieron premedicación con esteroides y no supusieron la interrupción del tratamiento. Conclusión: Teniendo en cuenta la gran variedad de enfermedades que pueden beneficiarse de la PF y el carácter esporádico de algunas de ellas, la publicación de la experiencia con esta modalidad terapéutica cobra gran importancia, ya que si incrementamos la descripción de series de casos por centros, podemos ayudar a ampliar el nivel de evidencia en términos de supervivencia y función renal en múltiples patologías infrecuentes. Nuestro estudio aporta una información útil y valiosa para la práctica clínica habitual y, sin duda, nos hace reflexionar sobre estrategias futuras que optimicen el pronóstico en nuestros enfermos (AU)

Introduction: Plasmapheresis (PP) is a therapeutic apheresis technique used in the treatment of various renal and systemic diseases with varying degrees of proven clinical efficacy. Objective: To review our experience with PP at the Hospital Universitario de Canarias, focused on effectiveness and safety results in different disease groups. Material and methods: A retrospective-descriptive study of patients treated with PP from 01/01/2006 to 31/12/2009 at the hospital. We analysed medical histories and demographic data (sex, age), biochemical parameters, underlying disease, volume and type of replacement used in the PP sessions (5% human albumin and/or fresh frozen plasma), complications with the technique, delay in starting PP treatment after suspected clinical diagnosis, number of PP sessions received, patient mortality, degree of renal impairment and evolution of renal function. Results: There were 51 patients studied, aged 50±18 years, of whom 60% were male; 331 PP sessions were performed. The diseases treated were grouped as: 11 vasculitis, 15 transplant immune activation, 5 haemolytic-uraemic syndrome (HUS), 7 idiopathic or thrombotic thrombocytopaenic purpura, 2 foetal Rh immunisations, 2 haematological diseases, 4 neurological diseases, among others. Overall mortality was 19.6% (n=10): 6 cases secondary to septic shock and the rest as a result of the evolution of the underlying disease, with 1 due to haemorrhagic shock in the renal biopsy area. There were no deaths in the transplant immune activation group. In the vasculitis group, there were 3 deaths (2 secondary to septic shock). Of the 10 patients who died, 9 did so within the first three months after diagnosis. Of the 26 renal biopsies performed, the most frequent indications were: vasculitis (23%), humoral rejection (42%), humoral rejection with calcineurin-inhibitor toxicity (12%) and HUS (8%), among others. Haemodialysis (HD) was required by 24 patients at the start of clinical symptoms: 9 of the 11 patients with vasculitis, 4 of the 5 patients with HUS and 5 of the 15 patients with transplant immune activation. At the end of evolution, 14 of them remained on the HD programme: 5 of the 11 patients with vasculitis, 2 of the 15 transplant patients and 3 of the 5 HUS patients. Significantly, patients who developed end kiney disease (EKD) in the vasculitis group were older and had higher creatinine at the onset of the disease. The transplant patients were monitored for anti-HLA class I or II before and after PP; there was a mean decrease of antibody titres in all but one patient; with an average decrease of 51% to 31%. In general, the PP technique was virtually free of complications. There were only 5 (3%) mild-moderate reactions to fresh plasma (perioral tingling and urticarial reactions) requiring pre-medication with steroids, but which did not lead to discontinuation of the treatment. Conclusion: Taking into account the wide variety of diseases that can benefit from PP and the nature of some of them, publishing our experience with this therapeutic method is of great importance. By increasing the description of case series by centre, we can add survival and renal function evidence in many uncommon diseases. Our study provides useful information for clinical practice and has also led us to reflect on future strategies to optimise outcomes in our patients (AU)

La ecografía carotídea es útil para predecir enfermedad coronaria y mortalidad en pacientes en hemodiálisis / Prognostic value of carotid intima media thickness and wall plaques in hemodialysis patients

Introducción: La enfermedad cardiovascular es la principal causa de muerte en los pacientes urémicos en hemodiálisis (HD). La ecografía carotídea es una herramienta sencilla y no invasiva para conocer el estado aterosclerótico de los pacientes. Objetivo: Conocer las asociaciones clínicas del grosor íntima-media carotídeo (GIM) y de la placa carotí- dea y su valor predictivo sobre el riesgo de enfermedad co- ronaria y la mortalidad. Metodología: Estudio prospectivo en el que se incluyeron 60 pacientes estables en HD (68 ± 13 años, 48% hombres, 50% diabéticos, tiempo en HD de 32 ± 11 meses) y 274 controles, semejantes en edad y sexo. El período de seguimiento fue de 66 ± 13 meses. Determi- naciones: Datos demográficos y clínicos, analítica general y niveles séricos de homocisteína y folato. Se midió el GIM mediante ecocardiografía 2D. Resultados: El GIM fue mayor en los pacientes en HD que en el grupo control (0,947 ± 0,308 frente a 0,619 ± 0,176 mm; p <0,001). El GIM se correlacionó con la edad (r = 0,268; p = 0,038), con la condición de diabético (r = 0,650; p <0,001) y la de hiper- tenso (r = 0,333; p = 0,012), pero no con colesterol total, HDL, LDL, triglicéridos, homocisteína o folato. Los pacien- tes con enfermedad coronaria, enfermedad vascular peri- férica o ictus tenían un GIM mayor que los que no presen- taban dichas afecciones (1,156 ± 0,371 frente a 0,875 ± 0,285 mm; p <0,001; 1,205 ± 0,374 frente a 0,911 ± 0,231 mm; p = 0,007; 1,195 ± 0,264 frente a 0,844 ± 0,251; p <0,001, respectivamente). Se encontraron datos similares respecto a la presencia de placas en la pared carotídea. Durante el período de seguimiento fallecieron 36 pacientes, 24 de los cuales (67%) por causa cardiovascular, cuyo GIM fue mayor (1,020 ± 0,264 frente a 0,858 ± 0,334 mm; p = 0,044). La supervivencia a la finalización del período de es- tudio fue significativamente mejor en el cuartil inferior de GIM (72%) que en el superior (20%). La presencia de pla- cas carotídeas fue predictor independiente de mortalidad cardiovascular. Conclusiones: El GIM y las presencia de pla- cas carotídeas se relacionan con algunos de los factores clá- sicos de riesgo cardiovascular como la edad, la diabetes o la hipertensión en pacientes urémicos. Su medición es útil para predecir la enfermedad coronaria y la mortalidad a largo plazo en los paciente urémicos (AU)

ntroduction: Cardiovascular disease and other complica- tions of atherosclerosis are the most common cause of death in patients with chronic renal failure in maintenance hemodialysis (MHD). Carotid ultrasonography is a simple no invasive tool to investigate the vascular system, by means of intima media thickness (IMT) measurement and carotid wall calcifications. Objective: To determine IMT and the presence of plaques, and their possible clinical re- lationships; finally we tried to investigate whether they would predict cardiovascular morbidity and mortality in patients in MHD. Methods: We studied 60 MHD patients (age 68 ± 13 years, 48% male, 50% diabetics, tiem on MHD 32 ± 11 months) and a control group of 274 people matched for age and sex. Follow-up period was 66 ± 13 months. Measurements: Demographic and clinical data, serum levels of homocysteine (tHcy), folic acid (FA) and B 6 and B 12 vitamins. IMT was measured by high-resolution B- mode ultrasonography. Results: IMT was higher in MHD patients than in those in the control group (0.947 ± 0.308 vs 0.619 ± 0.176 mm; P <0.001). IMT was related with age (r = 0.268; P = 0.038), diabetic (r = 0.650; P <0.001) and hy- pertensive condition (r = 0.333; P = 0.012), but not wih lipids, tHcy or FA. Similar findings were found with the presence or not of carotid plaques but serum LDL-choles- terol levels were also related (r= –0.280; P = 0.031). Patients who suffered from coronary artery disease, peripheral ar- tery disease or stroke had higher IMT than those without those events (1.156 ± 0.371 vs 0.875 ± 0.285 mm; P <0.001; 1.205 ± 0.374 vs 0.911 ± 0.231 mm; P = 0.007; 1.195 ± 0.264 vs 0.844 ± 0.251; P <0.001 respectively). Something similar ocurred with the presence of plaques. During the follow- up period 36 patients (60%) died, 67% of them due to car- diovascular causes. IMT was higher in patients who expired than those who survived (1.020 ± 0.264 vs 0.858 ± 0.334 mm; P = 0.044). The survival rate during the observation was significantly lower in the final IMT fourth (20%) than in the first (72%) (P = 0.014). The presence of carotid plaques was an independent predictor of cardiovascular mortality. Conclusions: These findings suggests that meas- urement of carotid IMT and the presence of wall plaques are useful tools to predict cardiovascular events and mor- tality in patients in MHD (AU)

[Carotid ultrasound: prevention of heart disease and mortality on haemodialysis]. / La ecografía carotídea es útil para predecir enfermedad coronaria y mortalidad en pacientes en hemodiálisis.

INTRODUCTION: Cardiovascular disease and other complications of atherosclerosis are the most common cause of death in patients with chronic renal failure in maintenance hemodialysis (MHD). Carotid ultrasonography is a simple non-invasive tool to investigate the vascular system, by means of intima media thickness (IMT) measurement and carotid wall calcifications. OBJECTIVE: To determine IMT and the presence of plaques, and their possible clinical relationships; finally we tried to investigate whether they would predict cardiovascular morbidity and mortality in patients in MHD. METHODS: We studied 60 MHD patients (age 68 +/- 13 years, 48% male, 50% diabetics, time on MHD 32 +/- 11 months) and a control group of 274 people matched for age and sex. Follow-up period was 66 +/- 13 months. MEASUREMENTS: Demographic and clinical data, serum levels of homocysteine (tHcy), folic acid (FA) and B6 and B12 vitamins. IMT was measured by high-resolution B-mode ultrasonography. RESULTS: IMT was higher in MHD patients than in those in the control group (0.947 +/- 0.308 vs 0.619 +/- 0.176 mm; P < 0.001). IMT was related with age (r = 0.268; P = 0.038), diabetic (r = 0.650; P < 0.001) and hypertensive condition (r = 0.333; P = 0.012), but not wih lipids, tHcy or FA. Patients who suffered from coronary artery disease, peripheral artery disease or stroke had higher IMT than those without those events (1.156 +/- 0.371 vs 0.875 +/- 0.285 mm; P < 0.001; 1.205 +/- 0.374 vs 0.911 +/- 0.231 mm; P = 0.007; 1.195 +/- 0.264 vs 0.844 +/- 0.251; P < 0.001 respectively). Something similar occurred with the presence of plaques. During the follow-up period 36 patients died (60%), 67% of them due to cardiovascular causes. IMT was higher in patients who died than those who survived (1.020 +/- 0.264 vs 0.858 +/- 0.334 mm; P = 0.044). The survival rate during the observation period was significantly lower in the final IMT fourth (20%) than in the first (72%) (P = 0.014). The presence of carotid plaques was an independent predictor of cardiovascular mortality. CONCLUSIONS: These findings suggests that measurement of carotid IMT and the presence of wall plaques are useful tools to predict cardiovascular events and mortality in patients in MHD.

Figura del coordinador sociosanitario: experiencia en una unidad satélite de hemodiálisis / No disponible

No disponible

Alteraciones del metabolismo mineral en la enfermedad renal crónica estadios III, IV y V(no en diálisis) / No disponible

• Con la progresión de la Enfermedad Renal Crónica (ERC)tiene lugar la aparición de alteraciones del metabolismo mineral.• La secuencia clásica de eventos se inicia con el déficit de síntesis de calcitriol y la retención de fósforo. Como consecuencia de ello, desciende el calcio serico y se estimula la hormona paratiroidea (PTH), produciendo en el hueso la Enfermedad Ósea de Alto Remodelado (AR), conocida como Osteítis Fibrosa, y en el otro extremo tenemos las formas de Bajo Remodelado (BR). Descritas más tardíamente, e inicialmente asociadas a la intoxicación alumínica, hoy las vemos principalmente en la población añosa y/o diabética, que en un ambiente urémico, presentan niveles relativamente bajos de PTH para mantener un remodelado óseo normal, también se incluye la Osteomalacia, que tras la desaparición de la intoxicación alumínica es rara de observar.• En las formas de AR el hiperparatiroidismo facilita la salida de calcio (Ca) y fósforo (P) del hueso, en tanto que el hueso adinámico limita la incorporación de Ca y Pal tejido óseo. Por lo tanto, ambas formas facilitan la disponibilidad de Ca y P, que se acaba depositando en (..) (AU)

• With progression of chronic kidney disease (CKD), disorders of mineral metabolism appear.• The classic sequence of events begins with a deficit of calcitriol synthesis and retention of phosphorus. As a result of this, serum calcium decreases and parathyroid hormone (PTH) is stimulated, producing in the bone the high turnover (HT)bone disease known as osteitis fibrosa while on the other extreme we find the forms of low turnover (LT) bone disease. Described later and initially associated with aluminum intoxication, these diseases are now seen primarily in older and/ordiabetic patients, who in a uremic setting have relatively low levels of PTH to maintain normal bone turnover. Osteomalacia is also included in this group, which after the disappearance of aluminum intoxication is rarely observed.• LT forms of hyperparathyroidism facilitate the exit of calcium(Ca) and phosphorus (P) from bone, whereas the adynamic bone limits the incorporation of Ca and P into bone tissue. Therefore, both forms facilitate the availability of Ca and (..) (AU)

Guía de nutrición en Enfermedad Renal Crónica Avanzada (ERCA) / No disponible

• La prescripción de la ingesta proteica en ERC es compleja por los conflictos potenciales existentes para retrasarla progresión de la ERC y preservar el estado nutricional. Proporcionar alrededor de 0,75 g proteínas/ kg/ día parece razonable en pacientes con FG > 30 mL (ERC estadios1-3). En estadios 4, 5 es recomendable proporcionar alrededor de 0,6 g/kg/día. Para frenar la progresión y minimizar la acumulación de toxinas urémicas.• Mantener una adecuada ingesta energética es esencial en todos los estadios de ERC.• La valoración del estado nutricional en ERC requiere de la utilización de múltiples marcadores, para valorar el estatus proteico, los depósitos de grasa, la composición corporal y la ingesta energética y proteica.• La Malnutrición Proteico Energética (MPE) puede ser considerada como una indicación para el inicio en terapia renal sustitutiva. Si la MPE se desarrolla o persiste a pesar de intentar optimizar la ingesta y no existe otra causa de malnutrición que la ingesta o anorexia urémica está indicada la iniciación de diálisis o el trasplante renal en pacientes con FG > 15 mL/ min.• El tratamiento nutricional para pacientes con ERC debería incluir valoración nutricional, educación y una planificación y seguimiento nutricional (AU)

• Prescription of protein intake in CKD is complicated by potential conflicts between goals to delay progression of CKD and preserve nutritional status. Providing a protein intake of about 0.75 g/kg/day appears reasonable in patients with GRF > 30 mL (CKD stages 1-3). In CKD stage 4 and 5, it is recommended to provide a protein intake of about0.6 g/kg/day to slow progression and minimize accumulation of uremic toxins.• Maintaining adequate energy intake is essential in all stages of CKD.• Assessment of nutritional status in CKD requires multiple markers to assess protein status, fat stores, body composition, and protein and energy intake.• PEM can be considered as an indication for the initiation of kidney replacement therapy. If PEM develops or persists despite attempts to optimize intake, and there is no apparent cause for malnutrition other than intake or anorexia, initiation of dialysis or kidney transplant is indicated in patients with GFR> 15 mL/min.• Nutritional treatment for patients with CKD should include nutritional assessment and education and nutritional planning and follow-up (AU)

El reto del control de la hiperfosfatemia en la enfermedad renal crónica / No disponible

Las alteraciones del metabolismo mineral en la Enferme-dad Renal Crónica (ERC) ejercen efectos adversos, en particular, sobre el esqueleto y el árbol cardiovascular. Dentro de las clásicas anormalidades bioquímicas, la hiperfosforemia juega un papel relevante. Sobre la glándula paratiroidea, estimula de forma directa (aumenta la síntesis y secreción de PTH, además de inducir proliferación celular) e indirecta (suprime la síntesis renal de calcitriol, disminuye la expresión del receptor de vitamina D y del sensor de cal-cio) la producción parathormona. A nivel de la célula mus-cular lisa vascular, induce su activación fenotípica, por lo que estas células adquieren un perfil osteoblástico, produciendo factores procalcificantes. Como consecuencia de ambos, numerosos estudios (retrospectivos) han demostrado un incremento de la mortalidad asociado a la hiperfosforemia (en general, P > 5,5 mg/dl). Por último, observaciones recientes sugieren una asociación directa entrefosforemia y progresión de la ERC. Sin duda, todos estos, son argumentos potentes a favor de un cada vez más estricto control del P en la ERC (AU)

Mineral metabolism abnormalities in chronic kidney disease(CRK) have adverse effects, particularly on the skeleton and cardiovascular system. Among the classic biochemical abnormalities, hyperphosphoremia plays a significant role. It stimulates parathyroid hormone production by the parathyroid gland both directly (it increases PTH synthesis and secretion and induces cell proliferation) and indirectly (it suppresses calcitriol synthesis by the kidneys and reduces vitamin D receptor and calcium sensor expression). It induces phenotypical activation of vascular smooth muscle cells, causing them to acquireanosteoblastic profile and produce procalcifying factors. As a result of both effects, numerous studies (retrospective) have shown an increase in mortality associated with hyperphosphoremia (usually P > 5.5 mg/dL). Finally, recent observations suggest a direct association between phosphoremia and CKD. Undoubtedly, all these are powerful arguments in favor of increasingly strict control of P in CKD (AU)

[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. / Alteraciones del metabolismo mineral en la enfermedad renal cronica estadios III, IV Y V (no en dialisis).

UNLABELLED: With progression of chronic kidney disease (CKD), disorders of mineral metabolism appear. The classic sequence of events begins with a deficit of calcitriol synthesis and retention of phosphorus. As a result of this, serum calcium decreases and parathyroid hormone (PTH) is stimulated, producing in the bone the high turnover (HT) bone disease known as osteitis fibrosa while on the other extreme we find the forms of low turnover (LT) bone disease. Described later and initially associated with aluminum intoxication, these diseases are now seen primarily in older and/or diabetic patients, who in a uremic setting have relatively low levels of PTH to maintain normal bone turnover. Osteomalacia is also included in this group, which after the disappearance of aluminum intoxication is rarely observed. LT forms of hyperparathyroidism facilitate the exit of calcium (Ca) and phosphorus (P) from bone, whereas the adynamic bone limits the incorporation of Ca and P into bone tissue. Therefore, both forms facilitate the availability of Ca and P, which ends up being deposited in soft tissues such as arteries. The link between bone disease and vascular calcifications in CKD is now a well-established phenomenon. 2. Diagnostic strategies Calcium, Phosphorus They have little capacity to predict underlying bone disease, but their regular measurement is decisive for therapeutic management of the patient, especially in the dose titration stages of intestinal phosphorus binders, vitamin D analogs or calcimimetics. Ideally, Ca++ should be used, but total Ca is routinely used. It is recommended to adjust albumin levels in the event of hypoalbuminemia (for each g/dL of decrease in albumin, total serum Ca decreases 0.9 mg/dL). The following formula facilitates rapid calculation of corrected total calcium: Corrected total Ca (mg/dL) = total Ca (mg/dL) + 0.8 [4-albumina (g/dL)]. Parathyroid hormone "Intact" PTH is the biochemical parameter that best correlates with bone histology (levels measured with the Allegro assay from Nichols Institute Diagnostics, no longer available). Various assays are currently available that use antibodies against different fragments of the molecule, but they have significant intermethod variability and have not been validated. A whole PT assay (1-84) is currently unavailable. A consensus to establish uniform criteria for PTH measurement remains to be established. During the dose titration stages of intestinal phosphorus binders, vitamin D analogs or calcimimetics, more frequent measurement may be required based on clinical judgment. Calcifediol (25(OH)D3) It is important to maintain adequate levels of 25(OH)D3 (> 30 ng/mL), since they will be the substrate for production of 1- 25(OH)2 D3, and their deficiency aggravates hyperthyroidism. Determining 25(OH)D3 levels every 6-12 months is a recommended guideline. Other markers of bone turnover (osteocalcin, total and bone alkaline phosphate, free pyridolines in serum, and C-terminal telopeptide of collagen) do not improve the predictive power of PTH and therefore their systematic use is not justified. Radiologic studies Radiologic studies are of little diagnostic utility, because biochemical changes precede radiologic changes. Systematic radiologic evaluation of the skeleton in asymptomatic patients is not justified at present. They are useful as the first step in the study to detect vascular calcifications and amyloidosis due to b2-microglobulin and in symptomatic and at risk patients to detect vertebral fractures. Bone densitometry: Dual energy x-ray absorptiometry (DEXA) is the standard method to determine bone mineral density (usually in the femoral neck and vertebrae). It provides information on changes in bone mineral content, but not on the type of underlying bone disease. It is useful for follow-up of bone mass or for the study of bone mass changes in the same patient. Its value as a predictor of the risk of fracture has not been demonstrated in patients on kidney replacement therapy or with advanced chronic kidney disease. It is indicated in patients with fractures or risk factors for osteoporosis. Bone biopsy: The "gold standard" for diagnosis of bone disease. With improved knowledge of the value of noninvasive parameters, its use is infrequent. INDICATIONS: Pathological fractures in the presence or absence of minor trauma. Symptomatic patients in the presence of incongruent clinical parameters. A typical case is the presence of unexplained hypercalcemia from systemic disease, with inconclusive serum PTH values (between 120-450 pg/mL as an estimated range). Evaluation and follow-up of cardiovascular calcifications There are no consensuated clinical practice guidelines for the evaluation and follow-up of extraosseal calcifications in CKD. The clinical tools for evaluation and follow-up of cardiovascular disease are used based on clinical judgment. The periodicity of follow-up has not been established . 3. Recommended biochemical values The biochemical values recommended in clinical practice guidelines for the evaluation of bone mineral metabolism are summarized in Figure 3. The recommended PTH values do not fully coincide with the K/DOQI guidelines. The wide variability in PTH values depending on the assays used has led us to expand the recommended PTH range in stage 3 and 4 CKD. 4. Treatment 4.1. Diet. The recommended diet for the patient with CKD is traditionally based on protein restriction and phosphorus restriction for control of mineral metabolism. A favorable circumstance is that there is a close relationship between protein and phosphorus intake. In CKD stages 3, 4 and 5, it is recommended to restrict phosphorus intake to between 0.8-1 g/day when serum levels of phosphorus and PTH are above the recommended range. This is approximately equivalent to a diet of 50-60 g of protein. This reasonable antiproteinuric strategy that also restricts phosphorus intake is nutritionally safe. What should we tell them to eat? In a practical and oversimplified way, we recommend the following daily intake: Animal proteins: 1 serving (100-120 g), dairy products: 1 serving (equivalent to 200-240 mL of milk or 2 yoghourts), bread, cereals, pastas (1 cup of pasta, rice or legumes + some bread or cookies), vegetables and fruits relatively freely, but with moderation. 4.2. Medication Vitamin D supplements should be provided if serum levels are less than 30 ng/mL. In Spain, vitamin D3 (cholecalciferol) is marketed as Vitamin D3 Berenguer 2,000 IU/mL of solution. Combinations of calcium with cholecalciferol are also available. Most of the dosage forms contain approximately 500 mg of Ca+ and 400 IU of cholecalciferol. Alternatively, calcifediol (25(OH)D3), as Hidroferol 100 mcg/mL, has been used, although the dose range is very variable and has not been established. 4.3. Phosphorus binders. Use if hyperphosphatemia occurs. Start with calcium-containing phosphorus binders (calcium carbonate or calcium acetate), which also provide calcium if dietary intake is inadequate. Do not exceed 1.5 g of Ca++ per day. The most used are calcium carbonate and calcium acetate. Calcium acetate shows a similar binding potency to calcium carbonate but with a lesser calcium overload, and thus would have certain advantages as well as its greater effect at different pH ranges. However, gastric intolerance is more frequent with this dosage form. Aluminum hydroxide may sometimes be required to control phosphoremia or the occurrence of hypercalcemia. Serum aluminum values should be maintained below 30 mcg/L. Avoid use for longer than 6 months and daily doses greater than 1.5 g. Sevelamer is associated with an increased risk of acidosis and has not been approved for use in predialysis stages. Lanthanum carbonate has been recently marketed in Spain, although its indication for use in the predialysis stage of CKD is still not approved. 4.4. Vitamin D derivatives. Indicated when PTH levels are elevated. A prerequisite for their use is that Ca and P serum levels are adequately controlled. Vitamin D derivates available in Spain are 1,25(OH)2D3 (Calcitriol)and 1a(OH)D3 (a-Calcidiol). Doses should be titrated until PTH levels are normalized. Phosphate binder doses often need to be increased because these vitamin D derivatives increase intestinal absorption of calcium and phosphorus. Low doses do not cause hypercalcemia or hyperphosphatemia and do not worsen the course of renal function. Recommended doses: Calcitriol 0.25 mcg every 48 hours and alpha-Calcidiol 0.50 mcg every 48 hours. Soon to be available on the Spanish market is the oral dosage form of paricalcitol (recommended initial dose of 1 mcg/24 h), with a lesser hypercalcemic and hyperphosphoremic effect. Clinical use of calcimimetics in the predialysis state is not yet recommended and is currently under investigation.

[Nutrition guidelines for advanced chronic kidney disease (ACKD)]. / Guia de nutricion en enfermedad renal cronica avanzada (ERCA).

Prescription of protein intake in CKD is complicated by potential conflicts between goals to delay progression of CKD and preserve nutritional status. Providing a protein intake of about 0.75 g/kg/day appears reasonable in patients with GRF > 30 mL (CKD stages 1-3). In CKD stage 4 and 5, it is recommended to provide a protein intake of about 0.6 g/kg/day to slow progression and minimize accumulation of uremic toxins. - Maintaining adequate energy intake is essential in all stages of CKD. - Assessment of nutritional status in CKD requires multiple markers to assess protein status, fat stores, body composition, and protein and energy intake. - PEM can be considered as an indication for the initiation of kidney replacement therapy. If PEM develops or persists despite attempts to optimize intake, and there is no apparent cause for malnutrition other than intake or anorexia, initiation of dialysis or kidney transplant is indicated in patients with GFR > 15 mL/min. - Nutritional treatment for patients with CKD should include nutritional assessment and education and nutritional planning and follow-up.

[The challenge of hyperphosphatemia control in chronic kidney disease]. / El reto del control de la hiperfosfatemia en la enfermedad renal crónica.

Mineral metabolism abnormalities in chronic kidney disease (CRK) have adverse effects, particularly on the skeleton and cardiovascular system. Among the classic biochemical abnormalities, hyperphosphoremia plays a significant role. It stimulates parathyroid hormone production by the parathyroid gland both directly (it increases PTH synthesis and secretion and induces cell proliferation) and indirectly (it suppresses calcitriol synthesis by the kidneys and reduces vitamin D receptor and calcium sensor expression). It induces phenotypical activation of vascular smooth muscle cells, causing them to acquire an osteoblastic profile and produce procalcifying factors. As a result of both effects, numerous studies (retrospective) have shown an increase in mortality associated with hyperphosphoremia (usually P > 5.5 mg/dL). Finally, recent observations suggest a direct association between phosphoremia and CKD.Undoubtedly, all these are powerful arguments in favor of increasingly strict control of P in CKD.

[A study using nondecalcified bone biopsy of the incidence and presentation forms of renal osteodystrophy]. / Estudio con biopsia ósea sin descalcificar de la incidencia y formas de presentación de la osteodistrofia renal.

BACKGROUND: Renal osteodystrophy (ROD) is a common complication of chronic renal failure. Fibrous osteitis and, to a lesser extent, osteomalacia are the predominant lesions. The aim of the present study was to evaluate the prevalence of the different forms of ROD. METHODS: Nondecalcified bone biopsies were evaluated in 100 patients with end-stage renal disease (57 in pre-dialysis and 43 on hemodialysis) in whom biochemical (calcium, phosphorus, alkaline phosphatase, parathyroid hormone) and histomorphometric studies were carried out. Bone biopsies were classified in four histological groups: mild, fibrous osteitis (FO), osteomalacia (OM) and mixed type (FO + OM). RESULTS: 96% of patients had histological findings of ROD with the following distribution: 41% mild; 30% FO; 14% OM; and 11% mixed. The most advanced types of ROD were seen in interstitial renal diseases. Pre-dialysis OM was associated with metabolic acidosis, a low phosphocalcic product and relative hypophosphoremia. Chronic aluminium poisoning was uncommon (7%) and was basically associated with OM. No instance of aluminium poisoning with osteodystrophy and bone fractures was seen. CONCLUSIONS: The most severe histological forms of OM were found in hemodialysis patients with persistent hypophosphoremia and associated with osteosclerosis.

[Recovery of kidney function in a female patient with severe lupus nephropathy]. / Recuperación de la función renal en una paciente con nefropatía lúpica severa.

The evolution of Lupus Nephritis to end-stage chronic renal failure is a frequent event. We report the case of a 28 years old patient with diffuse proliferative lupus nephritis with crescents formation and rapid decline of renal function without response to steroids, immunosuppressors and plasmapheresis. After 10 weeks of continued hemodialysis, during which the patient received 30 mg of prednisone in alternate days, renal function recovered spontaneously, and after 1 year of follow-up plasma creatinine is maintained in 2.5 mg/dl.

Osteomalacia in chronic renal failure before dialysis.

Bone biopsies taken from 327 patients before the start of dialysis have been correlated with clinical and biochemical findings to test various theories about the aetiology of osteomalacia. Two groups of patients, 100 with osteomalacia and 100 with pure osteitis fibrosa, have been compared in detail. Osteomalacia is associated with chronic pyelonephritis or obstruction as primary renal disease, and with acidosis, hypocalcaemia and normophosphataemia (as opposed to hyperphosphataemia). We have found no association between osteomalacia and known duration or severity of uraemia and in a small series of observations we have not confirmed previous reports of a close association between osteomalacia and depressed plasma 25(OH) cholecalciferol values.